Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4540 Retrospective analysis of somatostatin receptors expression in cohort of thoracic neuroendocrine neoplasms with immunohistochemistry method or PET/CT Ga68 DOTA-TATE

Introduction: Somatostatin receptors (SSTRs) expression in cohort of thoracic neuroendocrine neoplasms (NENs) is still not fully described. We attempted to evaluate the SSTR expression by IHC and PET/CT with Ga68 DOTA-TATE, as well as the sensitivity of both methods.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Vorobeva M, Zhulikov Y, Markovich A, Gorbunova V,

Keywords: NEN, thoracic, SSTR, IHC, DOTATATE, lung, thymus, mediastinum, LCNC, NET,

#4484 Experiences of combining narrative care and case care in the nursing of patients with neuroendocrine tumours

Introduction: Patients with neuroendocrine tumours have a long course of disease, facing not only physical pain but also complex psychological changes.

Conference:

Presenting Author: Tang Y

Authors: Xie W, Gu T, Tang Y, Liu G, Zhu Y,

Keywords: neuroendocrine tumour, narrative care, case care,

#4436 Application of novel wound materials in symptom management of patients with neuroendocrine tumours

Introduction: Neuroendocrine tumours can occur in multiple parts of the body, and management faces challenges.

Conference:

Presenting Author:

Authors: Liu G, Gu T, Tang Y, Xie W, Zhu Y,

Keywords: neuroendocrine tumour, novel wound materials, symptom management,

#4426 A case of giant neuroendocrine tumour of unknown primary site

Introduction: The liver is a common site for metastatic neuroendocrine tumours. NETs primary to the liver are rare, and it is difficult to determine whether a neuroendocrine tumour in the liver is primary or metastatic in patients in whom no tumour has been found elsewhere.

Conference:

Presenting Author: Yingmei T

Authors: Jieting D, Yanping Z, Yingmei T, Rongfang T, Yan W,

Keywords: neuroendocrine tumour, primary hepatic neuroendocrine tumour, metastatic,